All In Biotech

Drug Trial Radar · NCT07857135

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid Tumors

A Phase Ⅰ/Ⅱ Study of Dose Escalation, PK Expansion, and Cohort Expansion to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Oct 3, 2026

Primary completion

Feb 3, 2029

Study completion Aug 3, 2029

Sponsor

Sponsor type
Industry
First posted
Oct 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multi-center, open-label, dose-escalation, dose-expansion, and cohort-expansion first-in-human Phase 1/2 study to evaluate the safety, tolerability, PK characteristics, and preliminary anti-tumor efficacy of SYS6088 in patients with advanced/metastatic solid tumors.

Conditions

  • Advanced/Metastatic Solid Tumors

Interventions

  • SYS6088Drug

    SYS6088, administered per protocol.

  • RegorafenibDrug

    Regorafenib, administered per protocol.

  • IvonescimabDrug

    Ivonescimab, administered per protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The occurrence and frequency of Dose-limiting toxicities (DLTs) DLTs during the studyTime frame: Up to 90 days after last administration
  2. The occurrence and frequency of Treatment-emergent adverse events (TEAEs)Time frame: Up to 90 days after last administration
  3. The maximum tolerated dose (MTD) of SYS6088 (MTD, if any)Time frame: Up to approximately 18 weeks after the first participant is enrolled
  4. The recommended Phase 2 dose (RP2D) of SYS6088Time frame: Up to approximately 36 weeks after the first participant is enrolled
  5. Objective remission rate (ORR) assessed by the investigator according to RECIST v1.1Time frame: Up to approximately 3 years
  6. The occurrence and frequency of TEAEsTime frame: Up to 90 days after last administration

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.